^* Cysticercosis Unit, Instituto Nacional de Ciencias Neurologicas, Lima, Peru
Department of Microbiology, Universidad Peruana Cayetano Heredia, Lima, Peru
Department of International Health, Johns Hopkins University Bloomberg School of Hygiene and Public Health, Baltimore, MD, USA
School of Veterinary Medicine, Universidad Nacional Mayor de San Marcos, Lima, Peru
^¶ Immunology Branch, Division of Parasitic Diseases, National Centers for Infectious Diseases, Centers for Disease Control and Prevention

Correspondence to:
Correspondence to:
Dr H H Garcia, Av H Delgado 430, SMP, Lima 31, Peru;
hgarcia@jhsph.edu

The first 150 words of the full text of this article appear below.

Cysticercosis, widely endemic in most developing countries, is now beginning to appear with some frequency in industrialised countries as a result of both increasing travel and globalisation. Fortunately, advances in diagnostic methods, clinical knowledge, and the epidemiology of taeniasis and neurocysticercosis have enriched our understanding of the evolution of this infection and the resulting disease. Modern neuroimaging can now demonstrate milder cases than hitherto, and epidemiological studies using computed tomography (CT) in endemic settings have revealed asymptomatic brain calcifications in 10–20% of the general population.^1–3 Neurologically symptomatic individuals attending health centres clearly represent only the tip of a sizable iceberg of infection.⁴ This article will summarise basic information that should allow neurologists to make the diagnosis and manage human neurocysticercosis.

WHERE (GEOGRAPHICAL DISTRIBUTION)

As the result of poor socioeconomic development and domestic pig raising, cysticercosis is highly endemic in most developing countries around the world (fig 1). Even in Europe, transmission (albeit . . . [Full text of this article]